NR1H4 and type 2 diabetes mellitus: Recent clinical study has shown that sevelamer reduced plasma glucose concentrations in patients with type 2 diabetes and suggested that its mechanisms were possibly involved in decreased intestinal and hepatic bile acid-mediated FXR activation [51].